In response to the Covid-19 outbreak, CryopAL, a subsidiary of Air Liquide, has tripled its production capacity and is preparing to further increase it to meet the needs of the growing number of patients who receive home healthcare services, and to equip facilities that do not have an existing piped oxygen network.
In the context of the evolving Covid-19 pandemic in Europe, CryopAL has mobilized its resources to increase production capacity for its Freelox vessels, which store and release medical liquid oxygen.
These vessels, which can hold 32 or 44 liters of liquid oxygen, enable patients to self-monitor their own treatment for about a week. Fabricated at its plant in Bussy-Saint-Georges, near Paris, the usual production capacity is around 100 vessels a week. Currently, capacity has been increased to 300 vessels a week. In addition, CryopAL stands ready to significantly increase its production further, if necessary, by concentrating its competencies on this activity. |